Brought to you by 
Teva acquires Sicor for $3.3bn in cash and stock
Oct 2003
Executive Summary
Teva Pharmaceutical Industries will acquire Sicor (generic injectable drugs) and merge it with one of its subsidiaries. Teva is paying $16.50 in cash and 0.19 of a Teva ADR (currently valued at $10.90 each) for each Sicor common share, for a total of $3.3bn.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Stock
- Payment Includes Cash
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva acquires Sicor for $3.3bn in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice